Cephalon Patent Suit Over Amrix Survives Dismissal

By Richard Vanderford

Law360, New York (March 15, 2010, 5:39 PM ET) -- A federal judge has ruled that a patent infringement suit against Anchen Pharmaceuticals Inc. over its plans to make a generic version of Cephalon Inc. muscle relaxant Amrix can go forward, largely denying an Anchen dismissal motion in the case, which is part of a multidistrict litigation.

The plaintiffs — Amrix patent owner Eurand Inc. and Cephalon subsidiary and patent licensee Anesta AG — have raised a sufficient controversy to allow the case to go forward, Judge Sue Robinson of the U.S. District Court for the...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles